Study summary · research use only
Inhibition of activin-like kinase 4/5 attenuates cancer cachexia associated muscle wasting
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This study used C2C12 skeletal muscle cells in vitro and a C26-CD2F1 mouse cachexia model in vivo to examine ALK4/5 receptor blockers SB431542 and GW788388, alone or combined with the IGF-I analogue LONG R3 (LR3) IGF-I, in cancer cachexia-associated muscle wasting. In vitro, differentiation index and mean nuclei count increased with SB431542, GW788388, and LR3 IGF-I. In vivo, GW788388 showed greater limiting of bodyweight, grip-strength, and gastrocnemius weight loss than SB431542, and downregulated Atrogin-1 expression to a level comparable to non-tumour-bearing mice. LR3 IGF-I treatment limited muscle mass loss but was associated with accelerated tumour growth. The authors report GW788388 was associated with reduced signs of cancer cachexia in this model, alongside downregulation of the ubiquitin ligase Atrogin-1.
Abstract
Cancer mediated activation of the ActRIIB-ALK4/5 heterodimer by myostatin is strongly associated with muscle wasting. We investigated in vitro and in vivo the efficacy of ALK4/5 receptor blockers SB431542 and GW788388 in preventing muscle wasting, and explored synergy with IGF-I analogue LONG R3 (LR3) IGF-I. In vitro, C2C12 skeletal muscle cells were treated with vehicle, SB431542, GW788388 and LR3 IGF-I. A C26-CD2F1 cachexia model was used to induce cachexia in vivo. Mice were allocated as non-tumour bearing (NTB) or C26 tumour-bearing (C26 TB) vehicle control, treated with SB431542, LR3 IGF-I, SB431542 and LR3 IGF-I, or GW788388 (intraperitoneally or orally). In vitro, differentiation index and mean nuclei count increased using SB431542, GW788388, LR3 IGF-I. In vivo, GW788388 was superior to SB431542 in limiting loss of bodyweight, grip-strength and gastrocnemius weight. and downregulated Atrogin-1 expression comparable to NTB mice. LR3 IGF-I treatment limited loss of muscle mass, but at the expense of accelerated tumour growth. In conclusion, treatment with GW788388 prevented cancer cachexia, and downregulated associated ubiquitin ligase Atrogin-1.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.